OR WAIT null SECS
March 22, 2024
The company is recalling one lot of the product because of the potential presence of silicone particulates.
March 21, 2024
More synthetic opioids have been placed under the strictest controls in the United Kingdom.
March 15, 2024
The draft guidance document provides support to sponsors with drugs in clinical development that treat the states of sporadic Alzheimer’s disease.
March 11, 2024
The Alliance will receive the NSF Regional Innovation Engines Development Award and $1 million in funding.
March 08, 2024
EMA plans to add 10 partners to its real-world data initiative, DARWIN EU, in 2024.
March 07, 2024
FDA has published final guidance documents regarding validation and development of analytical procedures.
New plans laid out by AstraZeneca will see £650 million ($828 million) be invested into the UK.
March 04, 2024
Accurately targeted immunotherapies through reliable neoantigen recognition enable personalized medicine development.
March 02, 2024
Wider life sciences industries in the UK and Europe are receiving favourable financial support from governing bodies.
February 28, 2024
Steffen Thirstrup, chief medical officer, EMA, emphasizes the importance of transparency in investigating potential safety issues of CAR-T therapies, while highlighting the need to balance regulatory diligence with maintaining trust within the community and among stakeholders.